

## Board Initiates Voluntary Administration

---

**Paradigm Biopharmaceuticals Ltd. (ASX: PAR) ("Paradigm" or "the Company")**, advises that its Board has initiated a voluntary administration process, with the support of Obsidian Global GP, LLC ("**Obsidian**"), to pursue a restructuring of the Company's balance sheet while its clinical program and available study data are reviewed.

The Board has resolved to appoint Hayden White and Chris Pattinson of FTI Consulting as Voluntary Administrators of the Company ("**Administrators**") pursuant to section 436A of the *Corporations Act 2001* (Cth), effective 29 September 2026.

The decision follows discussions with Obsidian regarding the financial implications of the interim clinical trial outcome and potential restructuring options. The Board has formed the view that the Company requires time to resolve the mismatch between current liabilities payable in the short term and the inherent long term value of the intellectual property portfolio.

### Proposed balance sheet restructuring

The Board intends, with the cooperation of the Administrators, to work with Obsidian and other relevant stakeholders to develop a proposal for a deed of company arrangement ("**DOCA**") for consideration by the Administrators and creditors. The objective is to restructure the Company's liabilities, preserve its intellectual property and available clinical data, and assess a viable path forward for the business.

A DOCA is an agreement between a company and its creditors that sets out how the company's affairs and debts will be dealt with. Any proposal would require creditor approval and execution of the deed, together with any other necessary approvals. There is no certainty that a DOCA will be approved or implemented, or what the outcome will be for shareholders and creditors.

The Administrators will take control of the Company's business, property and affairs, undertake an independent assessment of its financial position and report to creditors on the options available. The Board will assist the Administrators with that assessment and the consideration of restructuring proposals.

During the administration, the powers of the Company's officers are suspended. The Company's securities remain suspended from trading on the ASX and are expected to remain suspended during the administration.

### Phase 3 Clinical Data Review

As previously announced, the Phase 3 PARA\_OA\_012 trial will not proceed as planned following the interim efficacy result falling below the pre-specified threshold required for continuation.

It is intended that the Company will continue analysing the available study data and reviewing its clinical program during the restructuring process, subject to the Administrators' assessment and

available resources. This work is intended to improve understanding of the interim outcome, including the impact of missing data, and inform the assessment of future development and commercial options.

### **Expected timetable and market updates**

The Company currently expects the overall clinical review and restructuring process to take at least eight weeks from the appointment of the Administrators. This estimate is subject to the progress of the review, the development and consideration of any restructuring proposal, and any necessary approvals or extensions to statutory timeframes. The process may take longer.

As noted above, the Company's securities remain suspended from trading on the ASX and are expected to remain suspended during the administration. The timetable for any reinstatement is uncertain and remains subject to ASX requirements and approval. Further updates will be provided as material developments occur.

The Directors thank the Company's employees and consultants for their tireless work in advancing the clinical program and supporting the Company through these difficult circumstances. The Board recognises the impact of this outcome on shareholders, employees, creditors and clinical trial participants, and appreciates their support.

-Ends-

### **Forward Looking Statements**

This Company announcement contains forward-looking statements, including statements regarding anticipated commencement dates or completion dates of preclinical or clinical trials, regulatory developments, regulatory approval, the proposed restructuring, the voluntary administration process, any deed of company arrangement and the expected timetable. These forward-looking statements are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company's control, and which may cause actual results to differ materially from those expressed in the statements contained in this announcement. Readers are cautioned not to put undue reliance on forward-looking statements.

---

Authorised for release by the Paradigm Board of Directors.

FOR FURTHER INFORMATION PLEASE CONTACT:

**Simon White**

Director of Investor Relations

Tel: +61 404 216 467

Paradigm Biopharmaceuticals Ltd.

ABN: 94 169 346 963

Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA

Email: [investorrelations@paradigmbiopharma.com](mailto:investorrelations@paradigmbiopharma.com)